Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a vasodilator agent. Its mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle.
## Primary Indications
* Treatment of peripheral vascular disease (e.g., intermittent claudication, arteriosclerosis obliterans, Buerger's disease) to improve blood flow.
* Considered for the management of premature labor (tocolytic agent), although evidence supporting its efficacy and safety for this indication is limited and it is not a preferred agent.
## Adult Dosing
* **Peripheral Vascular Disease:** Typically 10-20 mg orally 3-4 times daily. Doses may be increased cautiously based on patient response.
* **Premature Labor (Off-label/Limited Evidence):** Dosing is variable and often individualized. Historically, doses like 10-20 mg orally every 4-6 hours have been used. This use is not FDA-approved and is generally superseded by other tocolytic agents with better safety and efficacy profiles.
## Pediatric Dosing
There is no established pediatric dosing for isoxsuprine hydrochloride. Use in pediatric patients is not recommended.
## Dose Adjustments
No specific dose adjustments are established for hepatic or renal impairment. Caution is advised in patients with significant renal or hepatic disease.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Use in the immediate postpartum period.
* Not recommended for use in patients with congenital heart defects or arrhythmias.
## Adverse Effects
Common adverse effects include:
* Nausea
* Vomiting
* Dizziness
* Hypotension
* Tachycardia
* Weakness
* Gastrointestinal upset
* Flushing
* Rash
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the hypotensive effects of antihypertensive medications. Monitor blood pressure closely.
* **Other Vasodilators:** Additive hypotensive effects may occur.
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral vascular disease improvement (e.g., increased walking distance, reduced pain).
* For off-label use in tocolysis, monitor uterine contractions and fetal well-being.
## Clinical Pearls
* Effectiveness for peripheral vascular disease is variable and evidence is not robust. It is often used as adjunctive therapy.
* Oral administration is preferred. Intramuscular injection is available but may cause local irritation.
* Use in premature labor is largely historical and not recommended due to limited efficacy and potential for adverse maternal and fetal effects compared to current tocolytic agents.
* May cause a transient increase in blood glucose levels.
***
**Disclaimer:** This information is intended for clinical use only and does not substitute for professional medical judgment. Always consult the most current prescribing information and relevant guidelines for complete details. Prescribing decisions should be based on individual patient assessment and local institutional protocols.
